Table 5.
Outcomes by CAR T-cell product.
| 2-Day LDC, Axi-cel N: 52 (%) |
3-Day LDC, Axi-cel N: 17 (%) |
p-value | 2-Day LDC, Tisa-cel N: 12 (%) |
3-Day LDC, Tisa-cel N:11 (%) |
p-value | |
|---|---|---|---|---|---|---|
| ORR | 34 (65) | 13 (76) | 0.551 | 10 (83) | 8 (73) | 0.640 |
| CR | 26 (50) | 9 (53) | 0.99 | 6 (50) | 6 (55) | 0.99 |
| CRS, Any Grade | 44 (85) | 16 (94) | 0.435 | 9 (75) | 5 (45) | 0.214 |
| CRS, Grade 2–4 | 28 (54) | 11(65) | 0.575 | 7 (58) | 3 (27) | 0.214 |
| ICANS, Any Grade | 28 (54) | 11 (65) | 0.575 | 6 (50) | 3 (27)_ | 0.40 |
| ICANS, Grade 2–4 | 23 (44) | 7 (41) | 0.99 | 4 (33) | 1 (9) | 0.575 |
ORR, Overall Response Rate (Partial Response + Complete Response); CR, Complete Response; CRS, Cytokine release syndrome; ICANS, Immune effector cell associated neurotoxicity syndrome; Axi-cel, axicabtagene ciloleucel; Tisa-cel, Tisagenlecleucel; LDC, lymphodepleting chemotherapy.